Primer Raynaud Sendromunda Akut Vasküler Komplikasyonlar ve Tedavi

Öz

Primer İdyopatik Raynaud sendromu, sıklıkla kızları etkileyen ve kollajen doku hastalıkları gibi diğer sistemik tablolara eşlik etmeyen Raynaud fenomenli hastaları tanımlar. Raynaud fenomeni daha çok distal ekstremiteler- de belirgin olan; kendiliğinden, soğuk veya fiziksel- emosyonel stresle tetiklenen üç fazlı soluklaşma-siyanoz- eritem bir reaksiyondur. Çocuklarda ender olarak görülen bu tablo, sıklıkla geri dönüşlü olmakla birlikte ciddi vaka- larda iskemi ve nekrozlara yol açabilir. Hastalığın idame tedavisinde kalsiyum kanal blokerleri kullanılırken acil tedavide antikoagülan, pentoksifilin, nitroprussit ve prazo- sin kullanılabilir. Özellikle soğuktan korumak ve distal ekstremiteleri sıcak tutmak koruyucu tedavide önemlidir. Bu yazıda akut arteryel iskemi ile gelen primer Raynaud sendromlu iki kız hastada acil tedavi ve koruyucu önlemler tartışılmıştır

Anahtar Kelimeler

• Primer Raynaud sendromu,vasküler komplikasyon,kalsiyum kanal blokerleri

Acute Vascular Complications and Treatment in Primary Raynaud’s Syndrome

Öz

Primary Raynaud’s syndrome includes the Raynaud’s phe- nomenon mostly affects girls and is not associated with connective tissue diseases. Raynaud phenomenon descri- bes triphasic color changes of pallor, cyanosis and erythe- ma limited to distal extremities triggered by physical- emotional stres. Although this phenomenon is reversible, progression to necrosis may develop in serious cases. While, Ca-Channel blockers are used for long-term the- rapy, anticoagulant agents, pentoxyphillin, nitroprusside and prazosine can be given for acute treatment. Keeping distal extremities warm and protecting from cold stres are important for prevention. In this study, acute and long-term treatment of acute arterial ischemia in two female patients with primary Raynaud’s syndrome have been presented

Anahtar Kelimeler

• Primary Raynaud’s syndrome,vascular complication,Ca-Channel blockers

Kaynakça

1. 1. Raynaud M. On local asphyxia and symmetrical gangrene of the extremities. Arc Gen Med 1874; 1:189.
2. 2. Cassidy JT, Zulian F. The systemic sclerodermas and related disorders. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB (eds), Textbook of Pediatric Rheumatology. Philadelphia: Elsevier Saunders, 2005: 442-81.
3. 3. Voulgari PV, Alamanos Y, Papazisi D, Christou K, Papanikolaou C, Drosos A. Prevalence of Raynaud’s phenomenon in a healthy Greek population. Ann Rheum Dis 2000; 59:206-10.
4. 4. Nigrovic PA, Fuhlbrigge RC, Sundel RP. Raynaud’s phenomenon in children: a retrospective review of 123 patients. Pediatrics 2003; 111:715-21.
5. 5. Burns EC, Dunger DB, Dillon MJ. Raynaud’s disease. Arch Dis Child 1985; 60:537-41.
6. 6. Quartier P. Raynaud’s phenomenon in children. Arch Pediatr 2004; 11:74-7.
7. 7. Wigley FW, Korn JH, Csuka ME, et al. Oral iloprost in patients with Raynaud’s phenomenon secondary to systemic sclerosis. Arthritis Rheum 1998; 41:670-7.
8. 8. Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ. Raynaud’s phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 1981; 95:288-92.

9. 9. Brand FN, Larson MG, Kannel WB, McGuirck JM. The occurrence of Raynaud’s phenomenon in a general population: the Framingham study. Vasc Med 1997; 2:296-301.
10. 10. Vayssairat M, Abuaf N, Baudot N, Deschamps A, Gaitz JP. Abnormal IgG cardiolipin antibody titers in patients with Raynaud’s phenomenon and/or related disorders: prevalence and clinical significance. J Am Acad Dermatol 1998; 38:555-8.
11. 11. Rodeheffer RJ, Rommer JA, Wigley F, Smith CR. Controlled double-blind trial of nifedipine in the treatment of Raynaud’s phenomenon. N Engl J Med 1983; 308:880-3.
12. 12. Belch JJ, Ho M. Pharmacotherapy of Raynaud’s phenomenon. Drugs 1996; 52:682-95.
13. 13. Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999; 42:2646-55.
14. 14. Hettema ME, Zhang D, Bootsma H, Kallenberg CG. Bosentan therapy for patients with severe Raynaud’s phenomenon in systemic sclerosis. Ann Rheum Dis 2007; 66:1398-9.